Medical-tech ventures demand a completely different mindset from traditional VC playbooks. Gabriel Sanchez, co-founder of Enspectra, breaks down the brutal reality: when your technology won't reach market for a decade, conventional return expectations become almost irrelevant. The challenge isn't just securing initial capital—it's architecting a survival strategy for the long haul. Patient capital, strategic milestones, and disciplined burn rates become your lifeline. For founders navigating extended development cycles, the question shifts from "how fast can we scale" to "how do we remain solvent while executing on deep innovation." It's a masterclass in endurance over speed, fundamentally reshaping how emerging biotech and med-tech entrepreneurs approach the fundraising journey.